Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
675.04M | 482.38M | 401.86M | 365.98M | 353.87M | Gross Profit |
664.16M | 475.89M | 396.47M | 360.70M | 348.29M | EBIT |
136.95M | 107.28M | 112.63M | 124.48M | 128.20M | EBITDA |
136.95M | 108.32M | 112.63M | 124.48M | 130.44M | Net Income Common Stockholders |
139.73M | 106.14M | 101.42M | 112.51M | 106.01M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
383.33M | 368.22M | 436.62M | 335.81M | 476.89M | Total Assets |
840.55M | 621.52M | 583.43M | 423.76M | 571.73M | Total Debt |
6.94M | 151.00K | 1.14M | 526.00K | 2.55M | Net Debt |
-120.73M | -135.40M | -435.48M | -335.29M | -474.34M | Total Liabilities |
160.96M | 114.81M | 81.59M | 47.95M | 48.39M | Stockholders Equity |
679.59M | 506.70M | 501.84M | 375.81M | 523.34M |
Cash Flow | Free Cash Flow | |||
195.90M | 126.90M | 119.91M | 167.42M | 150.73M | Operating Cash Flow |
198.07M | 127.04M | 120.32M | 167.89M | 151.97M | Investing Cash Flow |
-177.60M | 90.91M | -114.33M | 136.13M | -119.26M | Financing Cash Flow |
-28.35M | -148.72M | -17.28M | -302.59M | 12.21M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $171.31B | 42.18 | 67.55% | 2.92% | 18.64% | -39.39% | |
74 Outperform | $5.85B | 44.60 | 23.55% | ― | 39.94% | 32.10% | |
68 Neutral | $10.69B | 33.14 | 14.16% | ― | 24.81% | 33.67% | |
64 Neutral | $125.40B | ― | -3.15% | ― | 11.64% | -114.72% | |
54 Neutral | $3.55B | ― | -214.50% | ― | 29.01% | 23.93% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
46 Neutral | $454.96M | ― | -63.37% | ― | -52.30% | 27.13% |
On February 26, 2025, Corcept Therapeutics announced its financial results for the fourth quarter and full year 2024, reporting a 40% increase in revenue to $675 million and a 33% rise in net income to $141.2 million compared to 2023. The company highlighted significant progress in its clinical development programs, including the submission of a New Drug Application for relacorilant for hypercortisolism and promising results from various studies, positioning relacorilant as a potential new standard of care. The announcement underscores Corcept’s strong financial performance and strategic advancements in its clinical pipeline, which could enhance its market position and impact stakeholders positively.